Compare ACADIA Pharmaceuticals Inc. (ACAD) vs The Coca-Cola Co K (KO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs The Coca-Cola Co K — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.72 (market cap $4.49B), while The Coca-Cola Co K trades at $84.43 (market cap $361.62B). The key difference: The Coca-Cola Co K is far larger — about 80.5× ACADIA Pharmaceuticals Inc.'s market cap, and The Coca-Cola Co K pays a 2.52% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | KO | |
|---|---|---|
Market Cap | $4.49B | $361.62B |
Sector | Health | Consumer Staples |
52-Week High | $28.06 | $84.14 |
52-Week Low | $20.06 | $65.67 |
Enterprise Value | $3.69B | $391.69B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Coca-Cola (KO) trades at $84.74, up 2.15% today, with a bullish technical outlook supported by moving averages and strong institutional buying. The company reported robust earnings, beating estimates for three consecutive quarters, with a net income margin of 27.8% in 2025. Recent news highlights steady demand and dividend reliability, with the stock near its consensus price target of $88.14.
KO offers a stable investment with consistent dividend growth and solid fundamentals, but faces risks from regional demand volatility and high valuation multiples. Analyst consensus is bullish, with 60% buy ratings, though the stock's current price proximity to resistance levels suggests limited near-term upside without new catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
